Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia

Dialysis and Transplantation

Volumn 35, Issue 11, 2006, Pages 660-671

  Pizzi, Laura T ^a   Patel, Nikita M ^a   Maio, Vittorio M ^a   Goldfarb, David S ^b   Michael, Beckie ^a   Fuhr, Joseph P ^c   Goldfarb, Neil I ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WIDENER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IRON;

ANEMIA; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSITIVITY ANALYSIS;

EID: 42349086609     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: 10.1002/dat.20064     Document Type: Article

References (27)

1. Esbach JW. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35:134-148.
2. National Kidney Foundation. KDOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182-S238.
3. USRDS Annual Data Report 2004. Available at: http://www.usrds.org/ adr_2004.htm. Accessed January 3, 2006.
4. MEDPAC: Medicare payment policy, end stage renal disease payment policies in traditional Medicare. In: MEDPAC Report to Congress. Washington, DC: MEDPAC, 2001:121-132.
5. End stage renal disease composite payment rate system. Available at: http://new.cms.hhs.gov/MedlearnProducts/downloads/ESRDCompRatePaymentSys.pdf. Accessed January 3, 2006.
6. 2003 Annual Report ESRD Clinical Performance Measures Project. Available at: http://63.241.27.79/esrd/2003_AR_final.pdf. Accessed January 3, 2006.
7. Sunder-Plassman G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070-2076.
8. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405-1416.
9. Macdougall IC, Hutton RD, Cavill I, et al. Poor response to treatment of renal anemia with erythropoietin corrected by iron given intravenously. Br Med J. 1989;299:157-158.
10. Nissenson AR, Charytan C. Controversies in iron management. Kidney Int. 2003;64(suppl 87):S64-S71.
11. Claims monitoring policy: erythropoietin/darbopoietin alfa usage for beneficiaries with end stage renal disease. Center for Medicare and Medicaid Services, 2005. Available at: www.cms.hhs.gov/coverage/8b5.pdf. Accessed December 2, 2005.
12. Levy R. The new CMS monitoring policy for anemia drug reimbursement: Implications for providers. Dial Transplant. 2006;35(2):88-90.
13. Xue JL, Ma JZ, Louis TA, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753-2758.
14. Ifudu O. Patient characteristics determining rHuEPO dose requirements. Nephrol Dial Transplant. 2002;17(suppl 5):38-41.
15. Cotter DJ, Stefanik K, Zhang Y, et al. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004;57:1086-1095.
16. Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866-876.
17. Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant. 2002;17(suppl 5):2-7.
18. Kalanatar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003;42:761-773.
19. Coladonato JA, Frankenfield DL, Reddan DN, et al. Trends in anemia management among US Hemodialysis patients. JAmSoc Nephrol. 2002;13:1288-1295.
20. Gunnell J, Yeun JY, Depner TA, et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63-72.
21. Yorgin PD, Belson A, Sarwal M, Alexander SR. Sodium ferric gluconate therapy in renal transplant and renal failure patients. Pediatr Nephrol. 2000;15:171-175.
22. Hollands JM, Foote EF, Rodriguez A, Rothschild J, Young S. Safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease. Am J Health Sys Pharm. 2006;63:731-734.
23. Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (≥250 mg) administration. Am J Kidney Dis. 2003;41:651-657.
24. Michael B, Coybe DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830-1839.
25. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;20(1):41-46.
26. Besarab A, Amin N, AhsanM, et al. Optimization of epoetin therapywith intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530-538.
27. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999;10:2029-2043.